科技通报

参考文献

[1] Cdc C F D C.Pneumocystis pneumonia—los angeles[J].MMWR Morbidity and Mortality Weekly Report,1981,30(21):250-252.

[2]殷大奎.中国艾滋病流行与防治对策[J].中国性病艾滋病防治，1998,4(4):145-147.

[3] Poku N K. HIV prevention:the key to ending AIDS by2030[J].The Open AIDS Journal,2016,10:65-77.

[4] UNAIDS.Global HIV&AIDS statistics[EB/OL].(2024)[2024-10-08]. https：//www. unaids. org/sites/default-/files/media_asset/UNAIDS_FactSheet_en.pdf

[5] Joint United Nations Programme on HIV/AIDS.UNAIDS data 2020[EB/OL].(2020)[2020-07-06]. https：//-www.unaids.org/sites/default/files/media_asset/2020_data_book_en.pdf.

[6] The National Health Commission of China 2020[EB/OL].(2020)[2024-10-08].http：//www.nhc.gov.cn/jkj/-new_index.shtml.

[7] World Health Organization. Global health sector strategies on,respectively,HIV,viral hepatitis and sexually transmitted infections for the period 2022-2030[EB/OL]. WHO;(2022)[202410-08]. https：//iris. who. int/bit-stream/handle/10665/360348/9789240053779-eng.pdf?sequence=1.

[8]王棠.基于湖北实践的艾滋病防治策略研究[D].武汉：武汉大学，2022.

[9] Zeng Y,Fan J,Zhang Q,et al.Detection of antibody to LAV/HTLV-III in sera from hemophiliacs in China[J].AIDS Research,1986,2(Suppl 1):S147-S149.

[10]汪宁.我国艾滋病预防控制的形势与面临的挑战[J].中华预防医学杂志，2004,38(5):291-293.

[11] Ji G P,Detels R,Wu Z Y,et al.Correlates of HIV infection among former blood/plasma donors in rural China[J].AIDS,2006,20(4):585-591.

[12]国务院.中国遏制与防治艾滋病规划（2024—2030年）[R].北京：国务院，2024.

[13] Bavinton B R,Pinto A N,Phanuphak N,et al.Viral suppression and HIV transmission in serodiscordant male couples:an international,prospective,observational,cohort study[J].The Lancet HIV,2018,5(8):e438-e447.

[14]Satcher Johnson A,Song R G,Hall H I.Estimated HIV incidence,prevalence,and undiagnosed infections in US states and Washington,DC,2010-2014[J]. Journal of Acquired Immune Deficiency Syndromes,2017,76(2):116-122.

[15] Narasimhan M,Kapila M. Implications of self-care for health service provision[J].Bulletin of the World Health Organization,2019,97(2):76-76A.

[16]韩孟杰，金聪，李敬云，等.扩大艾滋病检测促进早检测专家共识[J].中国艾滋病性病，2021,27(11):1202-1206.

[17]曾艳，万彬，赵霞，等.中国大学生HIV检测意愿的Meta分析[J].中华医院感染学杂志，2024,34(7):961-967.

[18]王莉.艾滋病患者预防保健和疾病控制中健康教育的应用效果分析[J].中国社区医师，2023,39(16):158-160.

[19]蔡雪云.艾滋病（AIDS）预防宣讲对AIDS预防控制中基础知识、传播途径及预防措施知晓情况的影响[J].口岸卫生控制，2024,29(2):25-28.

[20] Canavese D,Polidoro M,Ferreira A R,et al.Confronting the infodemic and fake news to end stigma and discrimination in HIV/AIDS:promoting zero discrimination practices in Brazil with massive open online course[J].Health Education&Behavior,2023,50(1):24-28.

[21]郭建勇.乌鲁木齐市艾滋病防治政策宣讲中存在的问题及对策[J].中共乌鲁木齐市委党校学报，2007(4):31-35.

[22] Mathers B M,Degenhardt L,Phillips B,et al.Global epidemiology of injecting drug use and HIV among people who inject drugs:a systematic review[J]. The Lancet,2008,372(9651):1733-1745.

[23] Strathdee S A,Stockman J K. Epidemiology of HIV among injecting and non-injecting drug users:current trends and implications for interventions[J]. Current HIV/AIDS Reports,2010,7(2):99-106.

[24] Adjei A A,Armah H B,Gbagbo F,et al. Correlates of HIV,HBV,HCV and syphilis infections among prison inmates and officers in Ghana:a national multicenter study[J].BMC Infectious Diseases,2008,8:33.

[25] Sullivan L,Levine B,Fiellin D,et al.Addiction and HIV in Kenya:A description of treatment serivces and integration[J].African Journal of Drug&Alcohol Studies,2007,6(1):17–26.

[26] Abdool R,Sulluman F,Dhannoo M. The injecting drug use and HIV/AIDS nexus in the republic of Mauritius[J].African Journal of Drug&Alcohol Studies,2006,5(2):108–116.

[27] Adelekan M,Lawal R.Drug use and HIV infection in Nigeria:A review of recent findings[J].African Journal of Drug&Alcohol Studies,2006,5(2):118–129.

[28] Plüddemann A,Parry C D H,Flisher A J,et al.Heroin users in cape town,South Africa:injecting practices,HIVrelated risk behaviors,and other health consequences[J].Journal of Psychoactive Drugs,2008,40(3):273-279.

[29] Reid S R.Injection drug use,unsafe medical injections,and HIV in Africa:a systematic review[J].Harm Reduction Journal,2009,6:24.

[30] Dewhurst J. Preventing HIV infection among injecting drug users in high-risk countries:an assessment of the evidence[J].AIDS Care,2010,22(3):397.

[31] Herget G. Methadone and buprenorphine added to the WHO list of essential medicines[J].HIV/AIDS Policy&Law Review,2005,10(3):23-24.

[32] World Health Organization. HIV/AIDS treatment and care:clinical protocol for Injecting Drug Users. HIV/AIDS treatment and care:Clinical protocol for the WHO European Region[EB/OL].(2007)[2024-10-08].https：//apps. who. int/iris/bitstream/handle/10665/341846/9789289072984-eng.pdf.

[33] Patrizia Carrieri M,Spire B.Harm reduction and control of HIV in IDUs in France[J].Lancet,2008,372(9637):448.

[34] Program Coordinating Board. Report of the TwentyFourth Meeting of the Programme Coordinating Board[EB/OL].(2009)[2024-10-08].https：//data.unaids.org/pub/informationnote/2009/20091005_24thpcb-report_final_en.pdf.

[35] Wood E,Kerr T,Marshall B D L,et al.Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users:prospective cohort study[J].BMJ,2009,338:b1649.

[36]张国龙，刘洋，梁妍，等.河南省AIDS防治成就与挑战——全球AIDS发现40周年记[J].河南预防医学杂志，2022,33(1):4-7,30.

[37]丁建平，刘晓燕，胡海洋，等.江苏省艾滋病防治工作30年发展报告[J].江苏预防医学，2022,33(1):1-2.

[38] Lin P,Fan Z F,Yang F,et al.Evaluation of a pilot study on needle and syringe exchange program among injecting drug users in a community in Guangdong,China[J].Chinese Journal of Preventive Medicine,2004,38(5):305-308.

[39] Fiedler S A,Oberle D,Chudy M,et al.Effectiveness of blood donor screening by HIV,HCV,HBV-NAT assays,as well as HBsAg and anti-HBc immunoassays in Germany(2008-2015)[J].Vox Sanguinis,2019,114(5):443-450.

[40] World Health Organization. Global Status Report on Blood Safety and Availability[EB/OL].(2016)[2024-10-08]. https：//iris. who. int/bitstream/handle/10665/254987/9789241565431-eng.pdf.

[41] Wang Ning.Current status and challenges of prevention and control of HIV/AIDS in China(in Chinese)[J].Chin J Prev Med,2004,38:291–293.

[42] Zhang D Y,Yin Y P,Feng T J,et al. HPV infections among MSM in Shenzhen,China[J].PLoS One,2014,9(5):e96364.

[43] UNAIDS.UNAIDS data[EB/OL].(2018)[2024-10-08].https：//www.unaids.org/sites/default/files/media_as-set/unaids-data-2018_en.pdf.

[44] Volmink J,Marais B.HIV:mother-to-child transmission[J].BMJ Clin Evid,2008,2008:0909.

[45] WHO,Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection[EB/OL](2013-06-30)[2024-10-08].https：//iris.who.int/bitstream/handle/10665/85321/9789241505727_eng.pdf.

[46] Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission,Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States[EB/OL](2024-01-31)[2024-10-08]. https：//clinicalinfo.hiv.gov/en/guidelines/perinatal/recommendations-arv-drugs-pregnancyoverview#:~:text=The%20Panel%20on%20Treatment%20of%20HIV%20During%20Pregnancy%20and%20Prevention.

[47] Havens P L,Mofenson L M,American Academy of Pediatrics Committee on Pediatric AIDS.Evaluation and management of the infant exposed to HIV-1 in the United States[J].Pediatrics,2009,123(1):175-187.

[48] Isichei C O.The role of trained birth attendants in delivering PMTCT services[J]. American Journal of Health Research,2015,3(4):232.

[49] Chizoba A F,Pharr J R,Oodo G,et al.Increasing HIV testing among pregnant women in Nigeria:evaluating the traditional birth attendant and primary health center integration(TAP-In)model[J].AIDS Care,2017,29(9):1094-1098.

[50] Olakunde B O,Wakdok S,Olaifa Y,et al.Improving the coverage of prevention of mother-to-child transmission of HIV services in Nigeria:should traditional birth attendants be engaged?[J]. International Journal of STD&AIDS,2018,29(7):687-690.

[51] Nsirim R O,Iyongo J A,Adekugbe O,et al.Integration of traditional birth attendants into prevention of mother-tochild transmission at primary health facilities in kaduna,north-west Nigeria[J].Journal of Public Health in Africa,2015,6(1):455.

[52] GU J. Prevention of mother-to-infant transmission of HIV:a new programme in China[J].Chin Med J,2003,116:1292.

[53] Jing W Z,Liu J,Liu M. Eliminating mother-to-child transmission of HBV:progress and challenges in China[J].Frontiers of Medicine,2020,14(1):21-29.

[54] National Health and Family Planning Commission of China2015 China AIDS response progress report[EB/OL].(2018-01-01)[2024-10-08].https：//www.unaids.org/sites/default/files/country/documents/C-HN_narrative_report_2017.pdf.

[55] UNAIDS.HIV/AIDS,Global Report:UNAIDS Report on the Global AIDS Epidemic:2012[EB/OL].(2012)[2024-10-08]. https：//www. unaids. org/sites/default/files/media_asset/20121120_UNA-IDS_Global_Report_2012_with_annexes_en_1.pdf.

[56] The Joint United Nations Programme on HIV/AIDS.Evidence review:Implementation of the 2016 to 2021 UNAIDS strategy:on the fast-track to end aids[R].Geneva:UNAIDS,2020.

[57]吴尊友.我国艾滋病经性传播新特征与防治面临的挑战[J].中华流行病学杂志，2018,39(6):707-709.

[58] Zhou Y H,Li D L,Lu D B,et al.Prevalence of HIV and syphilis infection among men who have sex with men in China:a meta-analysis[J]. BioMed Research International,2014,2014:620431.

[59] Yuan R,Cheng H,Chen L S,et al.Prevalence of different HIV-1 subtypes in sexual transmission in China:a systematic review and meta-analysis[J].Epidemiology and Infection,2016,144(10):2144-2153.

[60] Ministry of Health.Update on the AIDS/STD epidemic in China and main response in control and prevention in October,2014[J]. Chinese Journal of AIDS&STD,2014,20(12):885.

[61] Wang Y,Li L L,Zhang G G,et al.Analysis on the intention of marriage and the influence factors among unmarried men who have sex with men[J].Zhonghua Liu Xing Bing Xue Za Zhi,2012,33(10):1031-1035.

[62] Zhang B,Li X F,Chu Q S,et al. Correlation between AIDS and homosexuals:a study of 2046 male homosexuals in nine major cities of China[J].The Chinese Journal of Human Sexuality,2008,17(8):6–10.

[63] Cai Y M,Pan P,Hong F C,et al.Survey of KABP on STD/AIDS among male sexual workers in Shenzhen City[J].China Tropical Medicine,2007,7(11):2131–2133.

[64] Chow E P F,Wilson D P,Zhang L.What is the potential for bisexual men in China to act as a bridge of HIV transmission to the female population? Behavioural evidence from a systematic review and meta-analysis[J].BMC Infectious Diseases,2011,11:242.

[65]陈祥生，姜婷婷.我国性传播疾病的流行与防治[J].皮肤科学通报，2021,38(1):1-7,105.

[66]郭美荣.浅析高危人群艾滋病的综合性防治[J].临床医药文献电子杂志，2018,5(19):97,99.

[67]张意清.高危人群艾滋病综合性防治的调查分析[J].中国医药科学，2013,3(13):59-60.

[68]潘玉娟.浅析高危人群艾滋病的综合性防治[J].世界最新医学信息文摘，2015,15(87):159-160.

[69] Glaspy S,Cosmaro L,Botsi C,et al. Integrating partner notification and contact tracing services across Europe:findings from the Integrate project[J]. BMC Infectious Diseases,2021,21(Suppl 2):796.

[70] Guidelines on HIV Self-Testing and Partner Notification:Supplement to Consolidated Guidelines on HIV Testing Services[M]. Geneva:World Health Organization,2016.

[71]李佳佳，李凌华，刘聪.HIV阳性男男性行为者性伴告知现状与提升策略[J].预防医学情报杂志，2024,40(11):1473-1478.

[72] World Health Organization. Guideline on when to start antiretroviral therapy and on preexposure prophylaxis for HIV[EB/OL].(2015)[2024-10-08].https：//www.who.int/publications/i/item/9789241509565.

[73] UNAIDS.In Danger:UNAIDS Global AIDS Update 2022[EB/OL].(2022)[2024-10-08].https：//ww-w.unaids.org/en/resources/documents/2022/in-danger-globalaids-update

[74] World Health Organization.Guidelines on long-acting injectable cabotegravir for hiv prevention[EB/OL].(2022)[2024-10-08].https：//www.who.int/publications/i/item/9789240054097.

[75] Xu J J,Han M J,Jiang Y J,et al.Prevention and control of HIV/AIDS in China:lessons from the past three decades[J]. Chinese Medical Journal,2021,134(23):2799-2809.

[76]司忆，刘春礼.知-信-行护理干预模式对艾滋病住院患者心理状态及自我管理能力的影响[J].护理实践与研究，2021,18(24):3705-3709.

[77]黄万红，黄欣欣.知信行护理与症状联合护理对艾滋病患者的干预效果[J].中国医药指南，2024,22(11):165-167.

[78] Consolidated Guidelines on HIV Testing Services:5Cs:Consent,Confidentiality,Counselling,Correct Results and Connection 2015[M/OL].Geneva:World Health Organization.(2015)[2024-10-08].https：//www.who.int/publications/i/item/9789241508926.

[79]中国疾病预防控制中心.全国艾滋病检测技术规范[Z].2020.

[80]朱召芹.新版《艾滋病和艾滋病病毒感染诊断》中临床实验室检测部分更新内容解读[J].上海医药，2020,41(11):17-20.

[81]张娜，刘丽萍，易志强，等.江西省659例男男性行为者尿液艾滋病匿名检测结果分析[J].中国艾滋病性病，2019,25(3):299-300.

[82]张国磊，张夏燕，梁欣，等.北京市石景山区996例男男性行为者尿液HIV-1抗体匿名检测结果分析[J].现代预防医学，2017,44(11):2080-2083.

[83] He X X,Liu G W,Xia D Y,et al.An innovative HIV testing service using the Internet:Anonymous urine delivery testing service at drugstores in Beijing,China[J].PLoS One,2018,13(2):e0192255.

[84] Xinhua Net. National Health Commission:My country's AIDS infection rate of the entire population is about 9out of 10,000(in Chinese)[EB/OL].(2018)[2024-10-08].https：//www.gov.cn/xinwen/2018-11/23/conten-t_5342852.htm.

[85] Larder B A,Kemp S D.Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine(AZT)[J].Science,1989,246(4934):1155-1158.

[86] Cozzi Lepri A,Sabin C A,Staszewski S,et al.Resistance profiles in patients with viral rebound on potent antiretroviral therapy[J]. The Journal of Infectious Diseases,2000,181(3):1143-1147.

[87] HuéS,Gifford R J,Dunn D,et al.Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-na?ve individuals[J].Journal of Virology,2009,83(6):2645-2654.

[88] Mourad R,Chevennet F,Dunn D T,et al.A phylotypebased analysis highlights the role of drug-naive HIVpositive individuals in the transmission of antiretroviral resistance in the UK[J]. Aids,2015,29(15):1917-1925.

[89] Zhukova A,Cutino-Moguel T,Gascuel O,et al.The role of phylogenetics as a tool to predict the spread of resistance[J].The Journal of Infectious Diseases,2017,216(suppl_9):S820-S823.

[90] Novak R M,Chen L,MacArthur R D,et al.Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected,treatment-naive patients:implications for routine resistance screening before initiation of antiretroviral therapy[J]. Clinical Infectious Diseases,2005,40(3):468-474.

[91] Geretti A M. Epidemiology of antiretroviral drug resistance in drug-na?ve persons[J].Current Opinion in Infectious Diseases,2007,20(1):22-32.

[92] Ross L,Lim M L,Liao Q M,et al.Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-na?ve HIV-infected individuals from 40 United States cities[J].HIV Clinical Trials,2007,8(1):1-8.

[93] Wheeler W H,Ziebell R A,Zabina H,et al.Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses,U. S.–2006[J].Aids,2010,24(8):1203-1212.

[94] Frentz D,Boucher C A B,van de Vijver D A M C.Temporal changes in the epidemiology of transmission of drugresistant HIV-1 across the world[J]. AIDS Reviews,2012,14(1):17-27.

[95] Gupta R K,Gregson J,Parkin N,et al.HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries:a systematic review and meta-regression analysis[J].The Lancet Infectious Diseases,2018,18(3):346-355.

[96] World Health Organization.HIV Drug Resistance Report2019[EB/OL].(2019-07-01)[2024-10-08].https：//-www. who. int/publications/i/item/WHO-CDS-HIV-19.21.

[97] Li Jianwei,Zhang Jing,Shao Ying,et al.Use and effects of case management in antiretroviral therapy(in Chinese)[J].Chin J Aids Std,2017(7):657–659.

[98] Parienti J J,Bangsberg D R,Verdon R,et al.Better adherence with once-daily antiretroviral regimens:a metaanalysis[J].Clinical Infectious Diseases,2009,48(4):484-488.

[99] Nachega J B,Parienti J J,Uthman O A,et al.Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection:a meta-analysis of randomized controlled trials[J]. Clinical Infectious Diseases,2014,58(9):1297-1307.

[100]Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV[EB/OL].(2018)[2024-10-08]https：//clinicalinfo.hiv.gov-/en/guidelines/adult-and-adolescent-arv.

[101] Thompson M A,Mugavero M J,Rivet Amico K,et al.Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV:evidence-based recommendations from an International Association of Physicians in AIDS Care panel[J]. Annals of Internal Medicine,2012,156(11):817-833.

[102]中华医学会感染病学分会艾滋病丙型肝炎学组，中国疾病预防控制中心.中国艾滋病诊疗指南（2021年版）[J].协和医学杂志，2022,13(2):203-226.

[103]高海英，周施施，尹志红，等.个案管理对艾滋病患者生存质量影响的研究进展[J].潍坊医学院学报.2023,45(4):316-319.

[104]李娜，张坤，赵丽娜，等.“零转介”AIDS诊疗管理模式的临床验证[J].河北医药，2024,46(10):1548-1551.

[105]Barlow J,Wright C,Sheasby J,et al.Self-management approaches for people with chronic conditions:a review[J]. Patient Education and Counseling,2002,48(2):177-187.

[106]Ramsey S,Ames E,Uber J,et al.A mobile health app to improve HIV medication adherence:protocol for a pilot randomized controlled trial[J]. JMIR Research Protocols,2019,8(11):e15356.

[107]谢红，肖璐，文静，等.手机干预提升HIV/AIDS病人服药依从性的效果评价[J].中国艾滋病性病，2019,25(12):1229-1233.

[108]韩英，陈红.HIV感染者/AIDS患者自我管理量表的汉化及信效度评价[J].上海护理，2019,19(7):5-9.

[109]黄琴，关建萍，李晓春，等.240例HIV/AIDS患者自我管理能力现状及影响因素分析[J].护理学报，2017,24(22):46-49.

[110]田敏，谢龙昇，魏薇，等.HIV感染者自我管理健康教育内容体系的构建[J].中国艾滋病性病，2023,29(9):992-996.

[111]Zabor E C,Reddy C A,Tendulkar R D,et al.Logistic regression in clinical studies[J]. International Journal of Radiation Oncology,Biology,Physics,2022,112(2):271-277.

[112]Wang H,Sheng L,Xu S H,et al.Develop a diagnostic tool for dementia using machine learning and non-imaging features[J].Frontiers in Aging Neuroscience,2022,14:945274.

[113]郑睿颖，刘根焰.机器学习在感染性疾病临床预测模型中的应用进展[J].中国血吸虫病防治杂志，2023,35(3):317-321.

[114]梁福鑫，徐杰.机器学习技术在HIV防治中的应用研究进展[J].中国艾滋病性病，2024,30(4):435-440.

[115]陶建华，方益荣，卢巧玲，等.绍兴市基于“互联网+”自检的男男性行为者队列随访干预效果评价[J].中国艾滋病性病，2020,26(9):958-961.

[116]Kanters S,Park J J H,Chan K,et al.Interventions to improve adherence to antiretroviral therapy:a systematic review and network meta-analysis[J].The Lancet HIV,2017,4(1):e31-e40.

[117]商丹丹.基于微信平台的延续护理模式在艾滋病患者中的应用效果分析[J].皮肤病与性病，2020,42(6):826-827.